-
Mashup Score: 0Hoffmann Discusses Deciding Factors for Treating Patients With CLL - 6 month(s) ago
In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH NOW: Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with #CLL. #leusm https://t.co/ZfQ23cGRfr
-
-
Mashup Score: 0Venetoclax Still Safe for CLL With COVID-19 Diagnosis - 6 month(s) ago
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Patients with #CLL who were treated with venetoclax generally presented with asymptomatic or mild cases of COVID-19 and a low 30-day mortality rate, indicating that venetoclax is a safe treatment option for CLL during the pandemic. #LEUSM https://t.co/KIlRh85FOO
-
-
Mashup Score: 4
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory #CLL. #LEUSM | @LoriLeslieMD @HMHNewJersey @JTCancerCenter https://t.co/CoolqUmSmF
-
-
Mashup Score: 9
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
At a Case-Based Roundtable event, Stanley M. Marks, MD, led a discussion examining the repercussions of cardiac adverse events among patients with #CLL undergoing treatment with a BTK inhibitor. #leusm | @UPMCHillmanCC https://t.co/4C6ZDch1Kq https://t.co/O7YGI6wFs0
-
-
Mashup Score: 3
Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with #CLL. #LEUSM | @NYOHPC @TheUSONetwork https://t.co/IGG16cwEai
-
-
Mashup Score: 0
A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
A real-world analysis identified that ibrutinib remains a valuable treatment option for patients with #CLL due to its efficacy and tolerability. #LEUSM https://t.co/Oljp7WrVxV
-
-
Mashup Score: 1
During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Marc S. Hoffmann, MD, @KUcancercenter, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory #CLL and the efficacy behind zanubrutinib. #LEUSM https://t.co/490Jl2uibY
-
-
Mashup Score: 3Venetoclax Monotherapy Shows Deep, Durable Responses in R/R CLL - 8 month(s) ago
Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Venetoclax given alone led to deep and durable responses in patients with relapsed or refractory #CLL, irrespective of prior treatment with a B-cell receptor-associated kinase inhibitor. #LEUSM https://t.co/RBoVclWbuC
-
-
Mashup Score: 4Zanubrutinib Improves Survival, Response in Patients With CLL - 8 month(s) ago
In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
In a matched adjusted indirect comparison of zanubrutinib vs acalabrutinib in patients with relapsed or refractory #CLL data showed that zanubrutinib had an advantage in PFS and complete response, and potentially improved overall survival. #leusm https://t.co/N5xXDRhoZF
-
Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with #CLL. #leusm | @KUcancercenter https://t.co/9ekB76vLIg